Benzinga's Top #PreMarket Gainers

shares rose 23 percent to $25.00 in pre-market trading following announcement of proposal from Alibaba Group Holding Ltd

of $26.60 per share.

shares climbed 13.42 percent to $36.00 in pre-market trading after the company reported results from the Phase 3 ACT DMD clinical trial of Translarna™ (ataluren) in patients with Duchenne muscular dystrophy. Barclays' Geoffrey Meacham maintained an Overweight rating on the company, with a price target of $100.

shares surged 7.43 percent to $14.75 in pre-market trading after gaining 4.97 percent on Thursday.

gained 6.01 percent to $3.00 in pre-market trading after jumping 15.51 percent on Thursday.

shares rose 2.53 percent to $40.52 in pre-market trading after the bank reported stronger-than-expected earnings for the third quarter.